Effectiveness and Persistence in SB4- and Reference Etanercept-Treated Rheumatoid Arthritis Patients in Ordinary Clinical Practice in Norway.
Glenn HaugebergGunnstein BaklandErik RødevandInger Johanne Widding HansenAndreas P DiamantopoulosAre Hugo PrippPublished in: Arthritis care & research (2023)
Outcomes for disease status/drug persistence at week 52 were similar between patients with RA treated with etanercept or SB4.
Keyphrases
- rheumatoid arthritis patients
- disease activity
- rheumatoid arthritis
- clinical practice
- systemic lupus erythematosus
- ankylosing spondylitis
- randomized controlled trial
- systematic review
- juvenile idiopathic arthritis
- newly diagnosed
- emergency department
- type diabetes
- adipose tissue
- adverse drug
- interstitial lung disease
- systemic sclerosis
- drug induced
- insulin resistance
- study protocol
- placebo controlled